SG11201702312UA - Heterocyclic compound - Google Patents

Heterocyclic compound

Info

Publication number
SG11201702312UA
SG11201702312UA SG11201702312UA SG11201702312UA SG11201702312UA SG 11201702312U A SG11201702312U A SG 11201702312UA SG 11201702312U A SG11201702312U A SG 11201702312UA SG 11201702312U A SG11201702312U A SG 11201702312UA SG 11201702312U A SG11201702312U A SG 11201702312UA
Authority
SG
Singapore
Prior art keywords
heterocyclic compound
heterocyclic
compound
Prior art date
Application number
SG11201702312UA
Inventor
Yoshihiro Banno
Masahiro Kamaura
Kazuaki Takami
Koichiro Fukuda
Shigekazu Sasaki
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of SG11201702312UA publication Critical patent/SG11201702312UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/38—One oxygen atom attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201702312UA 2014-10-24 2015-10-22 Heterocyclic compound SG11201702312UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014217770 2014-10-24
PCT/JP2015/079782 WO2016063933A1 (en) 2014-10-24 2015-10-22 Heterocyclic compound

Publications (1)

Publication Number Publication Date
SG11201702312UA true SG11201702312UA (en) 2017-05-30

Family

ID=55760964

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201702312UA SG11201702312UA (en) 2014-10-24 2015-10-22 Heterocyclic compound

Country Status (37)

Country Link
US (4) US10214498B2 (en)
EP (2) EP3848353A1 (en)
JP (2) JP6588027B2 (en)
KR (1) KR102490156B1 (en)
CN (2) CN115197160A (en)
AR (1) AR104342A1 (en)
AU (2) AU2015336480B2 (en)
BR (1) BR112017007138A2 (en)
CA (1) CA2965465C (en)
CL (1) CL2017000944A1 (en)
CO (1) CO2017003699A2 (en)
CR (1) CR20170160A (en)
CY (1) CY1123842T1 (en)
DK (1) DK3210973T3 (en)
DO (1) DOP2017000098A (en)
EA (1) EA033446B1 (en)
EC (1) ECSP17026687A (en)
ES (1) ES2848999T3 (en)
HR (1) HRP20210320T1 (en)
HU (1) HUE053443T2 (en)
IL (2) IL285105B2 (en)
LT (1) LT3210973T (en)
MA (2) MA53568A (en)
MX (2) MX2017004629A (en)
MY (1) MY183209A (en)
PE (1) PE20170669A1 (en)
PH (1) PH12017500747B1 (en)
PL (1) PL3210973T3 (en)
PT (1) PT3210973T (en)
RS (1) RS61504B1 (en)
SG (1) SG11201702312UA (en)
SI (1) SI3210973T1 (en)
TN (1) TN2017000097A1 (en)
TW (2) TWI749661B (en)
UA (1) UA121871C2 (en)
WO (1) WO2016063933A1 (en)
ZA (1) ZA201703344B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53568A (en) 2014-10-24 2022-02-23 Takeda Pharmaceuticals Co DRUGS FOR THE TREATMENT OF OPHTHALMIC DISEASES
CN110650738B (en) 2017-03-20 2023-05-09 博德研究所 Compounds and methods for treating parasitic diseases
EP3829575A4 (en) * 2018-08-01 2022-07-20 The Trustees of Columbia University in the City of New York Rbp4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout
CN111690695A (en) * 2020-05-19 2020-09-22 浙江工业大学 Enzymatic microfluidic online synthesis method of 3-phenylaminopropylhydroxamic acid
CN111690698A (en) * 2020-05-19 2020-09-22 浙江工业大学 Method for synthesizing 3- (benzo [ d ] [1,3] dioxo-5-amino) propyl hydroxamic acid by two-step serial flow
WO2022256301A1 (en) * 2021-06-01 2022-12-08 Stargazer Pharmaceuticals, Inc. Methods and compounds for treating subjects with stargardt disease
CN116286900B (en) * 2022-10-28 2024-04-26 昆明理工大学 Acetic acid permease A gene RkAcpa and application thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625970A (en) 1968-04-17 1971-12-07 Cutter Lab 1-(disubstituted phenyl or benzyl)-1h-indazol-3-yloxyacetic acid
US5239080A (en) 1989-02-08 1993-08-24 Takeda Chemical Industries, Ltd. Oxazole compounds and their use as antidiabetic and bone-reduction inhibitory agents
EP0440183A1 (en) * 1990-02-01 1991-08-07 Takeda Chemical Industries, Ltd. Oxazole compounds, their production and use
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
AU1285499A (en) 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
AR035016A1 (en) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd COMPOSITION OF AZOL PROMOTER OF PRODUCTION / SECRETION OF NEUROTROFINE, COMPOSITE PRODROGA OF THE SAME, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THE SAME TO PREPARE THIS LAST.
WO2001025228A1 (en) 1999-10-07 2001-04-12 Tadeka Chemical Industries, Ltd. Amine derivatives
EP1228067B1 (en) 1999-11-10 2004-07-14 Takeda Chemical Industries, Ltd. 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
GB0020351D0 (en) 2000-08-17 2000-10-04 Catalyst Biomedica Ltd Treatment of hyperproliferative diseases
DE10149568A1 (en) 2001-10-08 2003-04-24 Consequence Gmbh Detection of amines, especially aminoacids formed in sequencing of peptides by Edman degradation, by forming reaction product with halo-substituted phenylisothiocyanate
WO2003042204A1 (en) 2001-10-19 2003-05-22 Takeda Chemical Industries, Ltd. Amine derivative
US20040214788A1 (en) 2003-03-11 2004-10-28 Raj Madhwa H.G. Treatment of prostate cancer
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
EP1658273B1 (en) 2003-08-20 2007-01-03 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
JP4869942B2 (en) 2003-12-11 2012-02-08 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド RBP4 in insulin sensitivity / resistance, diabetes and obesity
WO2005120583A2 (en) 2004-06-14 2005-12-22 Wisconsin Alumni Research Foundation Method for preventing or treating cardiac hypertrophy
EP2277516A1 (en) 2004-06-23 2011-01-26 ReVision Therapeutics, Inc. Retinyl derivatives for treating ophtalmic conditions
US20080033053A1 (en) 2004-07-22 2008-02-07 Wolfgang Curt D Cross-Reference To Related Applications
WO2006042252A2 (en) 2004-10-08 2006-04-20 Potentia Pharmeceuticals, Inc. Viral complement control proteins for eye disorders
RU2009101646A (en) 2006-06-22 2010-07-27 Сирион Терапьютикс, Инк. (Us) METHODS OF TREATMENT OF OPHTHALMOLOGICAL PATHOLOGICAL CONDITION OF THE MILKING EYE
AU2008268409B2 (en) 2007-06-26 2013-12-05 Lexicon Pharmaceuticals, Inc. Compositions comprising tryptophan hydroxylase inhibitors
US20090005381A1 (en) 2007-06-26 2009-01-01 Philip Manton Brown Methods of treating serotonin-mediated diseases and disorders
US7973079B2 (en) 2007-09-27 2011-07-05 Revision Therapeutics, Inc. Methods and compounds for treating retinol-related diseases
WO2009042444A2 (en) 2007-09-27 2009-04-02 Sirion Therapeutics, Inc. Methods and compounds for treating retinol-related diseases
WO2009051244A1 (en) * 2007-10-18 2009-04-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
US8541388B2 (en) 2008-05-22 2013-09-24 Isis Pharmaceuticals, Inc. Methods for modulating expression of RBP4
EP2295406B1 (en) * 2008-05-30 2014-04-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP2012523461A (en) * 2009-04-13 2012-10-04 アイアールエム・リミテッド・ライアビリティ・カンパニー Compositions and methods for modulating retinol binding to retinol binding protein 4 (RBP4)
BRPI1013763A2 (en) * 2009-04-16 2015-08-25 Takeda Pharmaceutical Compound or salt thereof, prodrug, pharmaceutical composition, retinol binding protein 4 lowering agent, agent for the prophylaxis or treatment of diabetes, and use of a compound
US20130012591A1 (en) 2009-10-28 2013-01-10 Revision Therapeutics, Inc. Prophylaxis of skin cancer with retinamides
CA2781888C (en) 2009-12-11 2019-06-18 Nono Inc. Agents and methods for treating ischemic and other diseases
KR102113960B1 (en) 2010-03-30 2020-05-21 베르선 코포레이션 Multisubstituted aromatic compounds as inhibitors of thrombin
EP2642998B1 (en) 2010-11-24 2020-09-16 The Trustees of Columbia University in the City of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
TR201906779T4 (en) 2011-05-12 2019-05-21 Proteostasis Therapeutics Inc Proteostasis regulators.
GB201205679D0 (en) 2012-03-30 2012-05-16 Dyson Technology Ltd A hand held appliance
WO2013166041A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Transthyretin ligands capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular
WO2014134127A1 (en) 2013-02-26 2014-09-04 Northeastern University Cannabinergic nitrate esters and related analogs
US20160030422A1 (en) 2013-03-14 2016-02-04 Konstantin Petrukhin Rbp4 antagonists for the treatment of age-related macular degeneration and stargardt disease
WO2014153643A1 (en) 2013-03-26 2014-10-02 The University Of British Columbia Compositions and methods for use thereof in the treatment of aniridia
EP3114109A4 (en) 2014-03-07 2017-10-18 The Johns Hopkins University Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
MA53568A (en) * 2014-10-24 2022-02-23 Takeda Pharmaceuticals Co DRUGS FOR THE TREATMENT OF OPHTHALMIC DISEASES
SI3209656T1 (en) 2014-10-24 2020-07-31 Bristol-Myers Squibb Company Indole carboxamides compounds useful as kinase inhibitors
MX2017005255A (en) 2014-10-24 2017-08-18 Bristol Myers Squibb Co Carbazole derivatives.
WO2016172631A2 (en) 2015-04-24 2016-10-27 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof
US10189797B2 (en) 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use

Also Published As

Publication number Publication date
EP3848353A1 (en) 2021-07-14
HUE053443T2 (en) 2021-06-28
AR104342A1 (en) 2017-07-12
MA53568A (en) 2022-02-23
JP6588027B2 (en) 2019-10-09
CN115197160A (en) 2022-10-18
CA2965465A1 (en) 2016-04-28
US10544111B2 (en) 2020-01-28
TWI749661B (en) 2021-12-11
IL251695A0 (en) 2017-06-29
LT3210973T (en) 2021-03-25
KR102490156B1 (en) 2023-01-18
TWI703131B (en) 2020-09-01
CR20170160A (en) 2017-06-15
SI3210973T1 (en) 2021-04-30
US20190119225A1 (en) 2019-04-25
TW201714876A (en) 2017-05-01
DK3210973T3 (en) 2021-02-08
PL3210973T3 (en) 2021-06-28
IL251695B (en) 2021-08-31
CN107108506B (en) 2022-06-21
CY1123842T1 (en) 2022-05-27
MX2017004629A (en) 2017-06-30
WO2016063933A1 (en) 2016-04-28
TW202042805A (en) 2020-12-01
EP3210973A1 (en) 2017-08-30
CL2017000944A1 (en) 2018-01-12
JPWO2016063933A1 (en) 2017-08-03
AU2015336480A2 (en) 2017-06-01
US10975043B2 (en) 2021-04-13
EP3210973B1 (en) 2020-12-02
CN107108506A (en) 2017-08-29
DOP2017000098A (en) 2017-07-15
IL285105B (en) 2022-11-01
AU2020204426A1 (en) 2020-07-23
PH12017500747A1 (en) 2017-10-30
US20210340114A1 (en) 2021-11-04
RS61504B1 (en) 2021-03-31
AU2015336480A1 (en) 2017-05-25
US20200157062A1 (en) 2020-05-21
AU2020204426B2 (en) 2022-02-03
CA2965465C (en) 2023-08-01
PH12017500747B1 (en) 2017-10-30
BR112017007138A2 (en) 2017-12-26
MA39688A (en) 2017-08-30
UA121871C2 (en) 2020-08-10
EA033446B1 (en) 2019-10-31
EP3210973A4 (en) 2018-04-25
EA201790912A1 (en) 2017-09-29
IL285105B2 (en) 2023-03-01
HRP20210320T1 (en) 2021-04-30
JP2020007347A (en) 2020-01-16
US20180237404A1 (en) 2018-08-23
ECSP17026687A (en) 2017-09-29
MX2021001188A (en) 2021-04-19
CO2017003699A2 (en) 2017-07-28
KR20170067791A (en) 2017-06-16
JP6995094B2 (en) 2022-02-21
PT3210973T (en) 2021-02-12
PE20170669A1 (en) 2017-06-06
MY183209A (en) 2021-02-18
MA39688B1 (en) 2021-02-26
ZA201703344B (en) 2018-08-29
IL285105A (en) 2021-08-31
TN2017000097A1 (en) 2018-07-04
AU2015336480B2 (en) 2020-04-02
ES2848999T3 (en) 2021-08-13
US10214498B2 (en) 2019-02-26

Similar Documents

Publication Publication Date Title
ZA201807249B (en) Heterocyclic compound
HK1223100A1 (en) Heterocyclic compounds
IL247018A0 (en) Heterocyclic compound
IL246838A0 (en) Fused heterocyclic compound
EP3187497A4 (en) Heterocyclic compound
IL248991B (en) Substituted dihydroisoquinolinone compounds
EP3205645A4 (en) Heterocyclic compound
EP3192791A4 (en) Heterocyclic compound
IL285105A (en) Heterocyclic compound
EP3110819A4 (en) Heterocyclic compounds
GB201413695D0 (en) Compound
GB201412238D0 (en) Compound
EP3239150A4 (en) Heterocyclic compound
RS60264B1 (en) Novel heterocyclic compound
IL254890B (en) Heterocyclic compound
GB201407694D0 (en) Compound
GB201416351D0 (en) Heterocyclic derivatives
EP3210971A4 (en) Heterocyclic compound
GB201418709D0 (en) Compound
GB201407693D0 (en) Compound
IL266099A (en) Heterocyclic compound
GB201413698D0 (en) Compound
GB201400579D0 (en) Compound
GB201403491D0 (en) New compound